Brief: ExpreS2ion JV AdaptVac Gets US Patent For Its Core Platform Technology
07/01/2020 07:52
Jan 7 (Reuters) - ExpreS2ion Biotech Holding AB EXPRS2.ST :
* EXPRES2ION'S JOINT VENTURE ADAPTVAC GRANTED US PATENT FOR
ITS
CORE PLATFORM TECHNOLOGY
* THIS CONFIRMS OVERALL PATENTABILITY AND PROPRIETARY
PROTECTION
OF ADAPTVAC'S ENTIRE PIPELINE AND FUTURE PROJECTS
Source text for Eikon: ID:nWkr23vtkB
Further company coverage: EXPRS2.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on ExpreS2ion Biotech Holding AB
See all newsBrief: Expres2ion Biotech To Raise SEK 19.3 Million From Warrants And Share Issue
Brief: ExpreS2ion Reports Q2 Loss Of SEK 9.7 Million
Brief: Expres2ion Biotech Says DSMB Recommends Expanding 450 Μg Cohort
Brief: Expres2ion Biotech Holding Q1 2026 Operating Income SEK 6.87 Mln
Brief: Expres2ion Updates ES2B-C001 Phase I Programme and Reports Additional Preliminary Immunogenicity and Safety Observations